New hope for kidney transplant patients: early rejection treatment studied
NCT ID NCT06291103
First seen Feb 23, 2026 · Last updated May 20, 2026 · Updated 16 times
Summary
This study looks at a new way to treat early signs of rejection in kidney transplant patients who develop antibodies against their donor kidney. About 290 adults will be randomly assigned to either switch to belatacept plus standard care or stay on their current medication. The goal is to see if belatacept can prevent kidney damage and improve long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT REJECTION are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.